Low bone mineral density, which may lead to osteoporosisĬataracts, glaucoma, or other vision problems Increased risk of infection, including fungus infection in the mouth (thrush) Increased risk of pneumonia in people who have COPD Increased trouble breathing right after use (paradoxical bronchospasm) Increased risk of asthma-related hospital stays, intubations, and death This medicine may cause the following problems: Tell your doctor if you have been exposed to chickenpox or measles. Tell your doctor about any immune system problems or infections, including herpes simplex in your eye, tuberculosis, or parasites. Tell your doctor if you are pregnant or breastfeeding, or if you have liver disease, cataracts, diabetes, glaucoma, heart disease, high blood pressure, heart rhythm problems, thyroid problems, seizures, or osteoporosis.
For more information, please visit: Important Safety Information for Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg, 250mcg/50mcg : We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's) We are very pleased to have now launched this product and will leverage the investments we have made and the experience we have gained through this process to develop a range of respiratory and other complex treatment options for patients and healthcare providers, helping us to continue to put better health, within reach, every day." Through the unwavering dedication of our employees and close collaboration with the Vectura team, we have developed a high quality and substitutable generic product for Advair Diskus ® that will improve availability of this critical medicine. Siggi Olafsson, Chief Executive Officer of Hikma, said "The approval of our generic version of Advair Diskus ® marks an important milestone in our strategy to develop more complex respiratory products. Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology.Īccording to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2 billion in the 12 months ending September 2020. 17, 2020 /PRNewswire/ - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline's Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.